about
Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.A qualitative study on acceptable levels of risk for pregnant women in clinical research.Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices.Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactation.Women in HIV cure research: multilevel interventions to improve sex equity in recruitment.Social media and pharmacovigilance: A review of the opportunities and challenges.Effects of supervised aerobic and strength training in overweight and grade I obese pregnant women on maternal and foetal health markers: the GESTAFIT randomized controlled trial.Pharmacologic studies in vulnerable populations: Using the pediatric experience.A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines.Participation in clinical trials improves outcomes in women's health: a systematic review and meta-analysis.The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.Ethics of studies of drugs in pregnancy.Immunization in pregnancy clinical research in low- and middle-income countries - Study design, regulatory and safety considerations.Data cleaning and management protocols for linked perinatal research data: a good practice example from the Smoking MUMS (Maternal Use of Medications and Safety) Study.Fertility-related research needs among women at the margins.Consent Processes for Mobile App Mediated Research: Systematic ReviewUtilizing Datasets to Advance Perinatal Research.Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.Pregnant women with substance use disorders: The intersection of history, ethics, and advocacy.Industry Perspective of Drug Development for Pregnant/Breastfeeding Women.Psychological and support interventions to reduce levels of stress, anxiety or depression on women's subsequent pregnancy with a history of miscarriage: an empty systematic review.Use of Over-the-Counter Medication among Pregnant Women in Sharjah, United Arab Emirates.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials.Differentiating Research, Quality Improvement, and Case Studies to Ethically Incorporate Pregnant Women.Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach.Towards an appropriate framework to facilitate responsible inclusion of pregnant women in drug development programs.How to obtain informed consent for research.Electronic Informed Consent to Facilitate Recruitment of Pregnant Women Into ResearchPhysiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspectiveThe direct and sustained consequences of severe placental hypoxia on vascular contractility
P2860
Q30244368-0B4D7630-8A34-4B6B-A1CF-58E13D501F96Q33691429-601CA49C-9342-451E-ABDA-F12D602FD45DQ34999895-861B1BBA-EADF-4811-8CAF-97F250717BC2Q34999915-8A2AD3D4-15EC-465B-96F4-DAAF8130C7BCQ35135985-869A4F55-7589-4D9F-A77A-728F370DB96DQ35953569-2D6A69E8-8B7A-4CC6-B96A-592E10BE1622Q36125558-870885EA-C56D-4420-B170-52813915086CQ36146714-9807CBFE-FAF5-4628-89ED-E36651D7FBDBQ36235896-946F9F30-5881-493F-BDD6-1431A5BB0D0DQ36251369-DB85B7B6-917D-485D-A4DD-D42179F59965Q36279548-65F84EAE-AFB1-40B8-8CAA-614A83CF7C18Q36326037-2A2A26A6-4494-4C88-B914-158D43ACD8C0Q36599597-455C7C67-6829-486A-8C4E-D74396353E79Q36635719-73D6CC21-2D88-4227-B857-AE11694E26AEQ38269943-A170F2B2-5CF0-41DF-9D2F-0E3D353924F5Q38370917-409510D2-38F1-465B-95AF-073E4D991932Q38374252-04F8A637-9AF8-4E5D-A4CE-7037EEAB6B42Q38567814-6A26B22E-1E40-4E3E-9F68-ACBFB13BE9DCQ38601759-54675BB4-D4DE-48F3-94D0-47936CBE800CQ38629124-53BF6B1C-51B0-4172-AD2D-0B1944E43A10Q38661049-FCCE6F54-40DE-443C-A8FD-D31B985384ECQ38757265-04C53D68-C0EE-4AAF-ADA3-F1160FD4D1B9Q38800893-3B2D4824-E78B-438B-A7BA-E43678D942FBQ39848038-DA1B2A26-9EE7-420B-9D40-A8E95A8B8FA2Q40052444-25EEFA89-14D2-4C79-A396-F698F909547BQ41215112-3B579968-4BB5-4BF9-B16E-92D335E77714Q46158508-F0072E95-C622-4DE2-8B14-4D0F1B798871Q47116619-B0261D74-58CD-470A-AE2F-5379C9295B80Q47240207-F0F72737-18F0-477E-B489-C039E22D9668Q47546991-59606467-CD5C-4BBA-9D33-F5FCF2615B06Q49843269-EA8CA664-F491-48AC-A0D2-516B37F4403BQ55260408-9E68D835-1C71-4BC4-A9A8-C3EF4175D8E9Q56530375-6C0B127C-831D-4C95-A161-01D67418E6D3Q58073610-8620DD15-EE4D-4977-A401-48FB70DF06E9Q58708934-EE4F5ACD-91D9-42F0-A8BA-36A07DD08070
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Enrolling pregnant women: issues in clinical research.
@ast
Enrolling pregnant women: issues in clinical research.
@en
type
label
Enrolling pregnant women: issues in clinical research.
@ast
Enrolling pregnant women: issues in clinical research.
@en
prefLabel
Enrolling pregnant women: issues in clinical research.
@ast
Enrolling pregnant women: issues in clinical research.
@en
P2093
P2860
P1476
Enrolling pregnant women: issues in clinical research.
@en
P2093
Janine A Clayton
Leyla Sahin
Mary C Blehar
Sara F Goldkind
P2860
P304
P356
10.1016/J.WHI.2012.10.003
P407
P577
2013-01-01T00:00:00Z